GW Pharmaceuticals Plc Stock News

Marijuana inhalables and edibles aren't the only things on the market anymore.

Marijuana stocks may still have some roadblocks until the U.S. market opens, but change is coming, and medical marijuana is leading the way. The post 7 Medical Marijuana Stocks For Your Waiting Room a

GW Pharmaceuticals PLC (NASDAQ:GWPH), the medicinal cannabis giant, has received European Commission (EC) approval for the treatment of seizures associated with tuberous sclerosis complex. The EC has

– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies

2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.

Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.

Could these areas see more gains ahead?

We highlight top performing ETF areas of the first quarter

Actively Managing Cannabis With Tim Seymour (Podcast)

Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.

Multiple high-profile companies may still be on the hunt for a deal.

The stock of GW Pharmaceuticals PLC (NAS:GWPH, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate

These are the top players in the expanding $19.6 billion U.S. marijuana market.

The cannabis-based pharmaceutical company agreed to be acquired.